查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2048241

血流導向動脈瘤治療市場－全球產業規模、佔有率、趨勢、機會、預測：按產品、最終用戶、地區和競爭對手分類，2021-2031年

Flow Diversion Aneurysm Treatment Market- Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product (FDS, Intrasaccular flow disruption devices), By End User (Hospitals, Specialty clinics), By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球以血流導向技術治療動脈瘤的市場預計將從 2025 年的 20.2 億美元成長到 2031 年的 31.8 億美元，複合年成長率為 7.86%。

這種先進的治療方法是在動脈瘤頸部植入高密度網狀支架，從而改變血流方向，使其沿著母血管流動。這种血流改變能夠促進動脈瘤囊內血栓形成，並有助於動脈壁的重建。推動該市場擴張的關鍵因素包括全球人口老化以及臨床實踐中人們普遍傾向於微創血管內治療方法而非傳統的外科夾閉術。例如，根據腦動脈瘤基金會2024年的數據，光在美國就有約670萬人患有未破裂的腦動脈瘤，凸顯了龐大的患者族群亟需有效的預防措施。

市場概覽
預測期 2027-2031
市場規模：2025年 20.2億美元
市場規模：2031年 31.8億美元
複合年成長率：2026-2031年 7.86%
成長最快的細分市場 FDS
最大的市場 北美洲

儘管這些臨床優勢推動了高普及率，但市場仍面臨許多障礙。這些障礙主要源自於植入式設備的高成本以及發展中國家醫療體系中普遍存在的複雜報銷制度。這些經濟障礙會限制患者獲得治療的機會，並延長新技術的核准流程，尤其是在價格敏感地區。此類限制可能會阻礙血流導向療法在全球範圍內的更廣泛應用，並可能將其應用範圍限制在富裕地區和專業醫療中心。

市場促進因素

血流導向裝置設計的技術進步，特別是表面改質植入的引進，正顯著地推動市場成長。這些創新技術旨在促進內皮化並最大限度地減少血栓形成（即導致血塊的傾向）。製造商正在開發先進的網狀結構，這些結構不僅能增強血流動力學旁路，還能減少長期雙重抗血小板治療的需求。這使得更廣泛的患者族群，包括出血高風險患者，都能得到治療。一個值得關注的例子是p64-MW-HPC表面改質血流導向裝置。 Phenox GmbH於2025年12月公佈的「COATING」試驗結果表明，該裝置具有與標準裝置相當的良好安全性，證明了這些新一代植入的臨床效用。這些技術進步直接解決了與裝置相關血栓症相關的傳統臨床問題，因此正在加速複雜顱內動脈瘤血管內治療方法的普及。

同時，全球腦血管疾病發生率的不斷上升正推動著對這些預防性介入療法的需求激增。中風和未破裂動脈瘤等疾病負擔的日益加重，迫使醫療系統優先考慮微創血流導向技術，以減輕動脈瘤破裂帶來的嚴重經濟和臨床後果。根據美國心臟協會於2025年1月發布的《2025年更新的心臟病和中風統計數據》，2012年至2022年間，美國中風死亡人數增加了28.7%，凸顯了有效預防性治療的迫切需求。對神經血管介入治療日益成長的需求在主要市場參與企業的強勁表現中得到了清晰的體現。例如，史賽克在2025年10月發布的2025年第三季財報中顯示，其醫療、外科和神經技術部門的淨銷售額成長了14.4%，這表明先進的介入神經放射學技術正在加速進入市場。

市場挑戰

由於血流導向裝置的初始成本高昂，加上複雜且往往不足的報銷機制，該市場面臨許多障礙。這些因素共同構成了巨大的經濟壁壘，阻礙了其廣泛市場滲透。醫院和採購部門通常預算緊張，而這些先進的高密度網狀支架的高昂成本往往超過了公共和私人醫療保險提供的打包支付範圍。當報銷率無法跟上新型醫療技術成本的成長時，醫療機構被迫承擔這些資金缺口，導致庫存難以維持，且器械使用核准流程更加嚴格。這種資金失衡最終限制了患者獲得必要的血流導向治療的機會，在發展中國家的醫療體系中，這一趨勢尤其突出，因為這些國家的醫療資源往往優先用於更傳統、成本更低的治療方法。

例如，介入神經放射學外科協會在2024年報告稱，使用血流導向裝置治療未破裂動脈瘤的平均植入費用約為12,400美元。如此高的固定成本對於採用固定收費模式的醫療機構而言是一個巨大的挑戰，阻礙了該療法的廣泛應用。因此，儘管血流導向裝置具有明顯的臨床益處，但其高昂的經濟負擔極大地限制了治療方法的普及，市場擴張主要局限於經濟富裕的地區或資金雄厚的專科醫療中心，因為這些機構能夠承擔如此高昂的費用。

市場趨勢

市場關鍵趨勢之一是將人工智慧驅動的模擬軟體日益融入神經血管介入手術的術前規劃階段，從根本上改變了手術準備方式。臨床醫生擴大利用這些複雜的計算模型，在支架置入前準確預測支架與血管壁的黏附情況以及血流動力學變化，從而確保選擇最佳支架並最大限度地減少器械尺寸誤差。這項創新對於降低血流導向裝置高成本帶來的經濟風險至關重要，因為精確的尺寸選擇可以減少器械錯位和額外矯正植入的需求。 2025年3月發表於《介入性神經放射學》雜誌的一項系統性回顧和Meta分析表明，虛擬模擬軟體在器械植入方面實現了高達96%的成功率，並將併發症率控制在4%的低水平，這充分證明了其在提高手術精準度和治療效果方面的重要作用。

同時，專為遠端和彎曲血管設計的低輪廓器械的研發正成為一大趨勢，有效擴大了可治療的患者群體，包括位於解剖結構難以觸及區域的動脈瘤患者。製造商正在開發新一代輸送系統，以容納較小的微導管，例如0.021英吋的平台。這些進步使介入外科醫生能夠順利通過Willis環內的急彎，這對於第一代大型器械而言是一個挑戰，從而能夠在不影響有效血流導向所需的徑向力的情況下治療遠端動脈瘤。發表於2025年11月《神經介入外科雜誌》的一項關於FRED X血流導引支架治療未破裂顱內動脈瘤的研究顯示，使用新一代低輪廓器械進行隨訪時，動脈瘤的適當閉塞率達到74.8%，證實了這些改進的輸送平台在治療實用性和有效性方面的臨床效用和有效性。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球血流導向動脈瘤治療市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 產品類別（FDS，膀胱內血流阻斷裝置）
    • 依最終用戶（醫院、專科診所）分類
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美血流導向動脈瘤治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲血流導向動脈瘤治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區血流導向動脈瘤治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲血流導向動脈瘤治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲血流導向動脈瘤治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章：全球血流導向動脈瘤治療市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Acandis GmbH
  • BALT Group
  • Cardinal Health Inc
  • Endologix LLC
  • Evasc Medical Systems Corp
  • Imperative Care Inc
  • InspireMD Inc
  • Johnson and Johnson
  • Lepu Medical Technology Beijing Co. Ltd
  • Medtronic Plc

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 18929

The global market for flow diversion aneurysm treatment is projected to grow from USD 2.02 Billion in 2025 to USD 3.18 Billion by 2031, demonstrating a compound annual growth rate (CAGR) of 7.86%. This advanced treatment involves implanting a dense mesh stent across the neck of an aneurysm, which redirects blood flow along the parent vessel. This redirection induces thrombosis within the aneurysm sac and facilitates the reconstruction of the arterial wall. Key factors fueling this market expansion include the increasing global elderly population and a notable clinical preference for minimally invasive endovascular techniques over traditional surgical clipping methods. For instance, data from the Brain Aneurysm Foundation in 2024 indicated that approximately 6.7 million individuals in the United States alone were living with an unruptured brain aneurysm, underscoring a significant patient demographic in need of effective preventive solutions.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 2.02 Billion
Market Size 2031USD 3.18 Billion
CAGR 2026-20317.86%
Fastest Growing SegmentFDS
Largest MarketNorth America

Despite the positive adoption rates driven by these clinical advantages, the market faces considerable obstacles, primarily stemming from the high cost of these implantable devices and the intricate reimbursement landscapes prevalent in developing healthcare systems. These economic barriers can restrict patient access to treatment and prolong the approval processes for novel technologies in regions sensitive to pricing. Such limitations potentially impede the broader global expansion and widespread availability of flow diversion therapies, confining their reach to more affluent areas or specialized medical centers.

Market Driver

Technological advancements in the design of flow diverter devices are significantly propelling market growth, particularly through the introduction of surface-modified implants. These innovations are engineered to enhance endothelialization and minimize thrombogenicity, which refers to the tendency to cause blood clots. Manufacturers are developing advanced mesh structures that not only improve the efficacy of hemodynamic diversion but also reduce the need for extended dual antiplatelet therapy. This allows for the treatment of a wider patient demographic, including those at a higher risk of bleeding. A notable example is the p64-MW-HPC surface-modified flow diverter, which, according to Phenox GmbH's 'COATING' trial results in December 2025, demonstrated a favorable safety profile comparable to standard devices, thereby validating the clinical utility of these next-generation implants. These engineering breakthroughs are directly addressing previous clinical concerns regarding device-related thrombosis, consequently encouraging greater adoption of endovascular solutions for complex intracranial aneurysms.

Simultaneously, the increasing worldwide incidence of cerebrovascular disorders is creating an urgent demand for these preventive interventional therapies. The growing burden of conditions like stroke and unruptured aneurysms is compelling healthcare systems to prioritize minimally invasive flow diversion techniques to mitigate the severe economic and clinical repercussions of aneurysm rupture. The '2025 Heart Disease and Stroke Statistics Update' from the American Heart Association in January 2025 reported a 28.7% rise in stroke deaths in the United States between 2012 and 2022, highlighting the critical need for effective preventive treatments. This escalating demand for neurovascular interventions is clearly reflected in the robust financial performance of leading market participants. For instance, Stryker reported a 14.4% increase in net sales for its MedSurg and Neurotechnology segment in the third quarter of 2025, as noted in October 2025, signaling accelerated commercial uptake of advanced neuro-interventional technologies.

Market Challenge

The market faces a significant hurdle due to the high acquisition costs of flow diversion devices, coupled with a complex and often inadequate reimbursement landscape, which collectively form substantial economic barriers hindering broader market penetration. Hospitals and purchasing departments frequently operate under stringent budget constraints, where the premium pricing of these advanced dense mesh stents can often exceed the bundled payments offered by both public and private health insurers. When reimbursement rates do not keep pace with the costs of new medical technologies, healthcare providers are forced to absorb these financial shortfalls, leading to reduced inventory availability and more rigorous approval processes for device utilization. This financial imbalance ultimately restricts patient access to essential flow diversion therapies, particularly in developing healthcare systems where funding is often prioritized for more traditional, lower-cost treatments.

For instance, the Society of NeuroInterventional Surgery reported in 2024 that the average implant cost for treating an unruptured aneurysm with a flow diverter was approximately $12,400. This substantial fixed cost for a single-use disposable unit poses a considerable challenge for institutions operating under fixed capitation payment models, making widespread adoption difficult. Consequently, despite the clear clinical advantages offered by flow diversion, the financial burden severely limits the scalability of the procedure, thereby confining market expansion primarily to affluent regions or well-funded specialized medical centers that can manage these high expenditures.

Market Trends

A key market trend involves the increasing integration of AI-driven simulation software in the pre-procedural planning phase of neurovascular interventions, which is fundamentally transforming how these procedures are prepared. Clinicians are increasingly utilizing these advanced computational models to accurately predict vessel wall apposition and hemodynamic changes before implantation, thereby ensuring optimal stent selection and minimizing device sizing errors. This innovation is crucial for mitigating the financial risks associated with the high cost of flow diverters, as precise sizing reduces the likelihood of device malposition or the need for additional corrective implants. According to a systematic review and meta-analysis published in Interventional Neuroradiology in March 2025, virtual simulation software achieved an impressive 96% success rate in device deployment while maintaining a low complication rate of 4%, thereby validating its significant role in enhancing procedural precision and outcomes.

Concurrently, another significant trend is the development of low-profile devices specifically designed for accessing distal and tortuous vasculature, which is effectively broadening the treatable patient population to include individuals with aneurysms located in previously inaccessible anatomical regions. Manufacturers are engineering next-generation delivery systems that are compatible with smaller microcatheters, such as 0.021-inch platforms. These advancements enable interventionalists to navigate sharp turns within the Circle of Willis, which were challenging for bulkier first-generation devices, allowing treatment of distal aneurysms without compromising the radial force necessary for effective flow diversion. As reported in the Journal of NeuroInterventional Surgery in November 2025, a study on FRED X flow diversion stenting for unruptured intracranial aneurysms demonstrated a 74.8% adequate occlusion rate at follow-up using a next-generation low-profile device, confirming the clinical viability and efficacy of these refined delivery platforms in managing complex neurovascular pathologies.

Key Market Players

  • Acandis GmbH
  • BALT Group
  • Cardinal Health Inc
  • Endologix LLC
  • Evasc Medical Systems Corp
  • Imperative Care Inc
  • InspireMD Inc
  • Johnson and Johnson
  • Lepu Medical Technology Beijing Co. Ltd
  • Medtronic Plc

Report Scope

In this report, the Global Flow Diversion Aneurysm Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Flow Diversion Aneurysm Treatment Market, By Product

  • FDS
  • Intrasaccular flow disruption devices

Flow Diversion Aneurysm Treatment Market, By End User

  • Hospitals
  • Specialty clinics

Flow Diversion Aneurysm Treatment Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Flow Diversion Aneurysm Treatment Market.

Available Customizations:

Global Flow Diversion Aneurysm Treatment Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Flow Diversion Aneurysm Treatment Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Product (FDS, Intrasaccular flow disruption devices)
    • 5.2.2. By End User (Hospitals, Specialty clinics)
    • 5.2.3. By Region
    • 5.2.4. By Company (2025)
  • 5.3. Market Map

6. North America Flow Diversion Aneurysm Treatment Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Product
    • 6.2.2. By End User
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Flow Diversion Aneurysm Treatment Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Product
        • 6.3.1.2.2. By End User
    • 6.3.2. Canada Flow Diversion Aneurysm Treatment Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Product
        • 6.3.2.2.2. By End User
    • 6.3.3. Mexico Flow Diversion Aneurysm Treatment Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Product
        • 6.3.3.2.2. By End User

7. Europe Flow Diversion Aneurysm Treatment Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Product
    • 7.2.2. By End User
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Flow Diversion Aneurysm Treatment Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Product
        • 7.3.1.2.2. By End User
    • 7.3.2. France Flow Diversion Aneurysm Treatment Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Product
        • 7.3.2.2.2. By End User
    • 7.3.3. United Kingdom Flow Diversion Aneurysm Treatment Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Product
        • 7.3.3.2.2. By End User
    • 7.3.4. Italy Flow Diversion Aneurysm Treatment Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Product
        • 7.3.4.2.2. By End User
    • 7.3.5. Spain Flow Diversion Aneurysm Treatment Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Product
        • 7.3.5.2.2. By End User

8. Asia Pacific Flow Diversion Aneurysm Treatment Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Product
    • 8.2.2. By End User
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Flow Diversion Aneurysm Treatment Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Product
        • 8.3.1.2.2. By End User
    • 8.3.2. India Flow Diversion Aneurysm Treatment Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Product
        • 8.3.2.2.2. By End User
    • 8.3.3. Japan Flow Diversion Aneurysm Treatment Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Product
        • 8.3.3.2.2. By End User
    • 8.3.4. South Korea Flow Diversion Aneurysm Treatment Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Product
        • 8.3.4.2.2. By End User
    • 8.3.5. Australia Flow Diversion Aneurysm Treatment Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Product
        • 8.3.5.2.2. By End User

9. Middle East & Africa Flow Diversion Aneurysm Treatment Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Product
    • 9.2.2. By End User
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Flow Diversion Aneurysm Treatment Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Product
        • 9.3.1.2.2. By End User
    • 9.3.2. UAE Flow Diversion Aneurysm Treatment Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Product
        • 9.3.2.2.2. By End User
    • 9.3.3. South Africa Flow Diversion Aneurysm Treatment Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Product
        • 9.3.3.2.2. By End User

10. South America Flow Diversion Aneurysm Treatment Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Product
    • 10.2.2. By End User
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Flow Diversion Aneurysm Treatment Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Product
        • 10.3.1.2.2. By End User
    • 10.3.2. Colombia Flow Diversion Aneurysm Treatment Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Product
        • 10.3.2.2.2. By End User
    • 10.3.3. Argentina Flow Diversion Aneurysm Treatment Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Product
        • 10.3.3.2.2. By End User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Flow Diversion Aneurysm Treatment Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Acandis GmbH
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. BALT Group
  • 15.3. Cardinal Health Inc
  • 15.4. Endologix LLC
  • 15.5. Evasc Medical Systems Corp
  • 15.6. Imperative Care Inc
  • 15.7. InspireMD Inc
  • 15.8. Johnson and Johnson
  • 15.9. Lepu Medical Technology Beijing Co. Ltd
  • 15.10. Medtronic Plc

16. Strategic Recommendations

17. About Us & Disclaimer